ChondroFiller is not available on the NHS — here is why

ChondroFiller™ is not available on the NHS, and no GP referral will open a route to it. As of mid-2026, the NHS has not commissioned this treatment, and there is no active NICE technology appraisal or pilot scheme under way for it.

The reason is structural rather than clinical. Before NHS hospitals can stock or fund a novel medical device, it must complete a health technology appraisal (HTA) or be incorporated into a national commissioning framework — a process that takes years and has not yet been initiated for ChondroFiller™. CE-marked Class III devices such as ChondroFiller™ can lawfully enter UK private practice without that review, and that is the route it has taken. Its clinical track record does not change the commissioning position: until a NICE appraisal concludes, NHS funding is not available regardless of the evidence.

For context, the only knee cartilage repair interventions currently commissioned by the NHS in England are Autologous Chondrocyte Implantation (ACI), approved by NICE in 2017, and Spherox, which became available via NHS England commissioning in 2018. Both are surgical, cell-based procedures suitable for specific defect sizes and patient profiles — they are not injectable scaffold treatments and serve a different part of the clinical pathway from ChondroFiller™.

What ChondroFiller™ does in the knee

Unlike corticosteroid or hyaluronic acid injections — both of which address pain symptoms without altering the underlying tissue — ChondroFiller™ is a CE-marked Class III medical device manufactured by Meidrix Biomedicals GmbH in Germany. It consists of purified Type I collagen that, once placed into a focal cartilage defect under ultrasound guidance in an outpatient setting, self-gels within minutes to form a stable scaffold inside the joint.

The mechanism is acellular matrix-induced chondrogenesis. The collagen scaffold contains no donor cells; instead, it recruits the patient's own progenitor cells from the surrounding synovium and subchondral bone, supporting the body's own repair processes at the defect site. Over subsequent months, the scaffold degrades progressively as native repair tissue forms in its place. Hyaluronic acid acts as a lubricant and does not alter cartilage structure; corticosteroid reduces acute inflammation; ChondroFiller™ provides a physical matrix for endogenous cellular repair — a fundamentally different role from either, and not a surgical procedure.

The treatment is suited to focal, well-defined cartilage lesions — typically Grade III–IV defects — rather than to widespread or diffuse osteoarthritis. Patients with bone-on-bone degeneration across the joint are unlikely to be candidates, as the scaffold requires a defined defect boundary to function as intended. Suitability is established at clinical assessment rather than by self-screening alone.

Which knee patients are likely to be suitable

Three practical questions help most patients gauge whether ChondroFiller™ is likely to apply to their situation — without yet needing a formal assessment.

How large and localised is the damage? Each unit of ChondroFiller™ is sized to cover approximately 3 cm² of defect surface. Most isolated cartilage injuries — a post-traumatic lesion, an osteochondral defect from a previous lateral impact, or localised Grade III–IV wear in one part of the joint — fall within the one-box range at £3,000. Larger focal defects may need two or three boxes; the precise volume is confirmed once imaging is reviewed. Where degeneration is diffuse, involving the full tibial plateau, the full medial or lateral compartment, or multiple compartments simultaneously, ChondroFiller™ is unlikely to be appropriate as a standalone treatment.

Is there an MRI-confirmed diagnosis? The scaffold requires a defined defect with recoverable surrounding tissue. A current MRI report — ideally one that characterises defect boundaries, depth, and subchondral bone integrity — is the baseline a specialist needs before a useful clinical conversation can take place.

What is the patient trying to avoid or preserve? ChondroFiller™ suits adults who want to protect or restore knee function without moving directly to surgery, across a wide age range. It is a regenerative scaffold pathway, not a pain-management injection, and it requires patience: cellular repair develops over months rather than days.

These questions orient rather than decide. A consultant assessment is needed to confirm suitability, interpret imaging, and match defect characteristics to the appropriate treatment volume.

Lincolnshire private access at Lincolnshire Knee Clinic

ChondroFiller™ is available at a small number of specialist private centres across the UK. This article is published by one of them — Lincolnshire Knee Clinic, part of the MSK Doctors group — and what follows describes how access works at that specific site, so readers can calibrate accordingly.

For patients in Lincolnshire and the East Midlands seeking the consultant assessment described above, that appointment does not require a journey south. The Sleaford site — MSK House, London Road, Silk Willoughby, NG34 8NY — offers ChondroFiller™ as part of a private non-surgical treatment menu, and no GP referral is needed: patients can self-refer and book directly.

The clinic runs a one-stop model. Consultation, onsite open MRI imaging review, and the injection itself can all take place in a single visit, removing the need for multiple return appointments — a practical consideration for most working patients.

Clinical access is consultant-led by Professor Paul Lee, who also directs ChondroFiller™ delivery at London Cartilage Clinic on Harley Street. Lincolnshire patients receive the same consultant-led assessment and treatment without travelling to London.

Appointment availability is governed by the private schedule rather than NHS referral queues or waiting lists. Patients can book directly at lincolnshireknee.co.uk.

What ChondroFiller™ costs and what insurance covers

For the great majority of patients, ChondroFiller™ is a self-funded cost. It carries no NHS reimbursement, and standard policy terms at both Bupa and AXA exclude it — so financial planning should start from that assumption.

Pricing is structured around defect volume, with three all-inclusive tiers:

• 1 box (~3 cm²): £3,000 — the most common requirement for an isolated focal lesion
• 2 boxes (~4.5 cm²): £5,500 — for larger single-site defects
• 3 boxes (~6 cm²): £8,000 — for extensive or multi-site focal damage; complex multi-compartment cases may reach approximately £9,800

Each tier covers everything: pre-injection consultation, imaging review, real-time ultrasound guidance, the ChondroFiller™ implant itself, IV antibiotic cover, and a six-week follow-up appointment. There are no separately billed extras.

Most patients with a single focal knee defect fall into the one-box range at £3,000. The volume needed is confirmed once a consultant has reviewed MRI imaging, so the tier cannot be finalised before that assessment.

Insurance — a nuanced picture

The exclusion from routine Bupa and AXA cover is the starting point, but it is not always the end of the conversation. CCSD codes W3111 (cartilage regeneration with collagen scaffold) and W8500 are recognised on UK insurer fee schedules, and case-by-case approvals have been reported with Bupa, Aviva, and WPA. The picture is fluid and insurer-specific. Any patient with active private medical cover should seek written pre-authorisation before treatment rather than assuming either a blanket exclusion or automatic approval.

What outcomes to expect and how to take the next step

Published evidence from multi-centre series reports 70–85% of patients achieving meaningful symptom relief at three to five years — a directional benchmark drawn from the device's global and UK private-centre data, not a figure tied to any single clinic or local dataset.

Supporting that range is a substantial real-world track record: approximately 20 years of European clinical use and over 19,000 cases worldwide. MRI-based MOCART scores of 70–87 have been reported in published series, indicating good defect fill and structural integration of repair tissue over time — a measure of how thoroughly the scaffold site has been incorporated, not just how a patient feels.

Recovery is outpatient in nature. There is no surgical wound, no theatre admission, and no general anaesthetic recovery. A rehabilitation phase is still expected — the scaffold integrates gradually, and the body's own repair processes develop over months rather than days. A treating consultant advises on return-to-activity timing based on defect size and individual progress.

ChondroFiller™ occupies a specific position in the treatment landscape: a well-evidenced injectable scaffold for focal cartilage damage that sits in a commissioning gap rather than an evidence gap. For patients with a defined focal lesion who have moved beyond what symptom-management injections can offer but are not yet ready for surgery, that distinction is the practical point of this treatment — and why the absence of an NHS pathway does not mean absence of a clinical option.

Lincolnshire Knee Clinic is part of the MSK Doctors group and accepts patients without referral — book an assessment at lincolnshireknee.co.uk.